Timothy Morris Biography and Net Worth

Director of DBV Technologies


Timothy E. Morris has been a member of DBV’s Board of Directors since 2021. He served as the Chief Operating Officer and Chief Financial Officer of Humanigen, Inc. since August 2020. Mr. Morris previously served on the Board of Directors of Humanigen as an Independent Director and Chairman of the Audit Committee from July 2016 to July 2020. He currently serves on the Board of Humanigen Australia Pty Ltd, Humanigen Ltd (UK) and Humanigen Europe Ltd, all wholly owned subsidiaries of Humanigen, Inc. Mr. Morris has 36 years of professional finance and accounting experience, including 22 years as Chief Financial Officer with public biotechnology companies (IOVA, ACRX, VVUS, QCOR). During his career he has raised over $2.2 billion in equity and convertible securities for seven companies, including four offerings for IOVA with over $1 billion in proceeds. Prior to Humanigen, Mr. Morris was CFO at Iovance where he oversaw an increase in market cap from $550 million to $4.2 billion (7x increase). He has extensive deal experience with 90 transactions and combined value in excess of $4.8 billion. Mr. Morris has been part of executive teams that were successful in the approval of 3 NDAs and 1 MAA. He is a CPA (inactive) and started his career from Chico State with Ernst & Young in Silicon Valley.

What is Timothy E. Morris' net worth?

The estimated net worth of Timothy E. Morris is at least $15.66 thousand as of August 25th, 2023. Mr. Morris owns 1,200 shares of DBV Technologies stock worth more than $15,660 as of December 5th. This net worth estimate does not reflect any other investments that Mr. Morris may own. Learn More about Timothy E. Morris' net worth.

How do I contact Timothy E. Morris?

The corporate mailing address for Mr. Morris and other DBV Technologies executives is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. DBV Technologies can also be reached via phone at (315) 542-7878 and via email at [email protected]. Learn More on Timothy E. Morris' contact information.

Has Timothy E. Morris been buying or selling shares of DBV Technologies?

Timothy E. Morris has not been actively trading shares of DBV Technologies within the last three months. Most recently, on Friday, August 25th, Timothy E. Morris bought 1,200 shares of DBV Technologies stock. The stock was acquired at an average cost of $15.20 per share, with a total value of $18,240.00. Following the completion of the transaction, the director now directly owns 1,200 shares of the company's stock, valued at $18,240. Learn More on Timothy E. Morris' trading history.

Who are DBV Technologies' active insiders?

DBV Technologies' insider roster includes Pharis Mohideen (Chief Medical Officer), Timothy Morris (Director), Adora Ndu (Director), and Daniel Soland (Director). Learn More on DBV Technologies' active insiders.

Are insiders buying or selling shares of DBV Technologies?

In the last twelve months, insiders at the sold shares 3 times. They sold a total of 1,461 shares worth more than $2,270.56. The most recent insider tranaction occured on July, 29th when insider Pharis Mohideen sold 464 shares worth more than $1,030.08. Insiders at DBV Technologies own 1.4% of the company. Learn More about insider trades at DBV Technologies.

Information on this page was last updated on 7/29/2025.

Timothy E. Morris Insider Trading History at DBV Technologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2023Buy1,200$15.20$18,240.001,200View SEC Filing Icon  
See Full Table

Timothy E. Morris Buying and Selling Activity at DBV Technologies

This chart shows Timothy E Morris's buying and selling at DBV Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DBV Technologies Company Overview

DBV Technologies logo
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Read More

Today's Range

Now: $13.05
Low: $12.96
High: $13.42

50 Day Range

MA: $13.96
Low: $9.14
High: $17.00

2 Week Range

Now: $13.05
Low: $2.74
High: $18.00

Volume

978,247 shs

Average Volume

248,892 shs

Market Capitalization

$469.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A